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Abstract
Introduction: This study aimed to evaluate whether lymphovas-
cular invasion (LVI) can replace lymph node (LN) involvement as 
a prognostic marker in patients who do not undergo lymph node 
dissection (LND) during surgery in patients with upper tract uro-
thelial carcinoma (UTUC). 
Methods: A total of 505 patients who underwent radical nephro-
ureterectomy (RNU) were recruited from four academic centres 
and divided into four groups: node negative (N0, Group 1); node 
positive (N+, Group 2); no LND without LVI (NxLVI-, Group 3); 
and no LND with LVI (NxLVI+, Group 4). 
Results: Patients in Group 2 had larger tumours, a higher incidence 
of left-sided involvement, more aggressive T stage and grade, and 
a higher positive surgical margin rate than patients in other groups. 
Pathological features (T stage and grade) were poorer in Group 
4 than in Groups 1 and 3. Compared to other groups, Group 2 
had the worst prognostic outcomes regarding locoregional/distant 
metastasis-free survival (MFS), cancer-specific survival (CSS), and 
overall survival (OS). LVI and LN status in Group 4 was not associ-
ated with MFS in multivariate analysis. Among Nx diseases, LVI 
was not an independent predictor of MFS or CCS. The small num-
ber of cases in Groups 2 and 4 is a major limitation of this study.
Conclusions: Clinical outcomes according to LVI did not correlate 
with those outcomes predicted by LN involvement in patients with 
UTUC. Therefore, LVI may not be used as a substitute for nodal 
status in patients who do not undergo LND at the time of surgery.
Introduction
The prevalence of upper tract urothelial carcinoma (UTUC) is 
approximately 5–10%.1-5 Approximately 20‒40% of patients 
initially present with locally advanced disease and lymph 
node (LN) metastases at the time of diagnosis.6-9 Recently, 
Margulis et al identified age, high tumour grade, high patho-
logical T stage, LN metastasis, sessile architecture, an infil-
trative growth pattern, and lymphovascular invasion (LVI) 
as independent prognostic indicators of disease recurrence 
and cancer-specific survival (CSS).8 Tumour stage, grade, 
and LVI are independent predictors of clinical outcome in 
patients with UTUC;10,11 however, knowledge of assessable 
prognostic factors in UTUC is still limited.
Radical nephroureterectomy (RNU) with excision of the 
ipsilateral bladder cuff is the treatment of choice for local-
ized UTUC.12 In most retrospective studies on UTUC treated 
by RNU, LVI is detected in approximately 20% of cases.13 
LVI is a critical step in the systemic dissemination of cancer 
cells.14 LVI is also associated with high stage and grade, and 
has a negative impact on UTUC prognosis.15-18 Metastasis of 
UTUC to regional LNs occurs frequently and is a significant 
predictor of oncologic outcomes. LN dissection (LND) is 
highly recommended in muscle-invasive UTUC;10,19 how-
ever, LND for UTUC is not universally performed. A recent 
study presented at the American Urological Association 
(AUA) annual meeting suggested that LVI is associated with 
LN involvement in patients with UTUC and may be used as a 
surrogate marker in patients who do not undergo LND at the 
time of surgery.20 In that study, no differences in oncologic 
outcomes were observed between node positive (N+) and 
LVI positive patients who did not undergo LND (NxLVI+); 
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however, limitations of the study, such as the small study 
population (n=131), prevent definitive conclusions.
To address this issue, a large multicentre cohort of patients 
with UTUC who underwent RNU was analyzed for the first 
time. The aim of the present study was to evaluate whether 
LVI can be used as a prognostic substitute for LN involve-
ment in patients who do not undergo LND during surgery 
in a large cohort. 
Methods
Study population
Data obtained from 505 patients who underwent RNU 
(open, 183 [36.2%], or laparoscopic, 322 [63.8%]) for 
UTUC at four institutions in Korea between March 2001 
and December 2013 were analyzed. All of the patients had 
com plete followup data available and were considered for 
the anal yses. To avoid the introduction of bias in the sur-
vival estimates, patients with previous or concurrent muscle-
invasive bladder cancer, those who received neoadjuvant 
chemotherapy, or those with evidence of distant metastasis 
at the time of diagnosis were excluded. Patients had under-
gone preoperative cystoscopy, urine cytology, and chest and 
abdominal-pelvic computed tomography (CT) scans. 
Surgery was performed according to the standard criteria 
for RNU. After RNU, bladder cuff resection was performed 
using standard procedures (i.e., an extravesical approach via 
a Gibson incision) as stipulated by each centre. LND was 
performed if lymphadenopathy was suspected upon preop-
erative imaging or observed during surgery. The majority of 
patients with non-organ-confined disease received cisplatin-
based adjuvant chemotherapy. Tumours were staged accord-
ing to the American Joint Committee on Cancer (6th edition) 
staging system.21 Tumour grades were assessed according 
to the 1998 World Health Organization classification sys-
tem.22 All specimens were histologically confirmed to be 
urothelial carcinoma. LVI was defined as the presence of 
tumour cells in an endothelium-lined space without under-
lying muscular walls.13 Tumour multifocality was defined 
as the synchronous presence of two or more pathologically 
confirmed tumours in any location (renal pelvis or ureter).23 
Followup regimen
Followup examinations included cystoscopy, urine cytology, 
chest X-ray, and CT scanning. Cystoscopy and urine cytolo-
gy were performed at three, six, and 12 months post- surgery, 
and yearly thereafter. Image analyses were  performed at 
three, six, and 12 months after RNU, and then every six 
months from 1‒5 years post-surgery. Scans were performed 
annually thereafter. In this study, locoregional/distant metas-
tasis was defined as a locoregion al recurrence or a new 
distant metastasis based on clinical and radiographic find-
ings. Metastasis-free survival (MFS) was defined as the period 
between surgery and the detection of locoregional recur-
rence, distant metastasis, or the study’s endpoint. Time to 
CSS was calculated as the time from surgery to the date of 
cancer-attributable mortality.
Statistical analysis
To evaluate patient outcomes, subjects were divided into 
node negative (N0, Group 1); node positive (N+, Group 2); 
no LND without LVI (NxLVI-, Group 3); and no LND with 
LVI present (NxLVI+, Group 4). For comparison of variables, 
differenc es in variables with continuous distributions across 
dichoto mous categories were assessed using ANOVA. The 
Fisher’s ex act and Pearson chi-square tests were used to 
evaluate the association between categorical variables. The 
Kaplan-Meier method was used to draw survival curves. The 
log-rank test was used to assess significance, with p≤0.05 
considered statistically significant. Potential prognostic fac-
tors were established by univariate analyses and only fac-
tors considered significant were entered into multivariate 
Cox proportional hazards regression models. All statistical 
analyses were performed using the SPSS v.18.0 (IBM Corp., 
Armonk, NY, U.S.).
Results
The mean age was 66.26 years. Of 505 patients included in 
the study, 94 (18.6%) had LVI. Regional LND was performed 
in 287 (56.8%) patients, of which 28 (9.8%) were N+. The 
number of patients in each group was: 259 (51.3%) in Group 
1, 28 (5.5%) in Group 2, 181(35.8%) in Group 3, and 37 
(7.3%) in Group 4.
Differences in pre- and postoperative characteristics 
among the groups stratified by the presence of LNs and 
LVI are summarized in Table 1. Regarding clinical N stage, 
most patients (78.6%) in Group 2 had positive LNs in the 
preoperative CT images. Patients in Group 2 also had larger 
tumours than those in the other groups. Considering the 
pathologic characteristics of the tumour specimens, statis-
tically significant differences were found for pathologic T 
stage (p<0.001), surgical margin status (p=0.015), multifo-
cality (p=0.008), and tumour grade (p=0.009). 
The median followup period was 38.4 months (interquar-
tile range [IQR] 15.6–56.5). One hundred and nine (109) 
patients (21.6%) received adjuvant systemic chemotherapy. 
During the followup period, 173 patients (34.3%) had blad-
der recurrence after a median followup time of 17.0 months 
(IQR 8.4–36.0). Overall, locoregional recurrence/distant 
metastasis occurred in 129 patients (25.5%) after a median 
period of 25.5 months (IQR 12.0–51.4). One hundred and 
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eleven (111) patients (22.0%) died; 88 deaths (17.4%) were 
directly related to cancer. Kaplan-Meier curves were used to 
assess bladder recurrence, MFS, CCS, and overall survival 
(OS) according to LN and LVI status. No statistically signifi-
cant differences in bladder recurrence were observed among 
the four groups (Fig. 1A). Group 2 had the worst prognostic 
outcomes regarding MFS and Group 4 patients had signifi-
cantly worse MFS than Groups 1 and 3 (Fig. 1B). LN and 
LVI status (Groups 2 and 4) was helpful in predicting MFS 
compared to Group 1 in univariate Cox analysis; however, 
Group 4 did not appear as an independent predictor of MFS 
(Table 2). Considering CCS and OS, the poorest oncologic 
outcomes were found in Group 2 (Figs. 2A and 2B), and no 
differences in CCS and OS were detected between Groups 
1 and 4 (Figs. 2A and B).
In the subgroup of patients with Nx disease (Group 3 
vs. Group 4), LVI status had a negative impact on MFS and 
CSS (p=0.032 and p=0.035, respectively; Figs. 1B and 2A); 
however, LVI was not an independent prognostic factor for 
MFS and CSS in multivariate analysis (supplementary Tables 
1 and 2). Among the patients who underwent LND (only 
including Groups 1 and 2), LVI was a significant prognostic 
Table 1. Differences in clinicopathological results among the four groups stratified by the presence of lymph nodes and 
lymphovascular invasion
Group 1 (n=259) Group 2 (n=28) Group 3 (n=181) Group 4 (n=37)
Age (years, mean ± SD) 66.05 ± 10.67 66.07 ± 9.40 65.69 ± 10.56 70.68 ± 9.09
BMI (kg/m²) 23.6 ± 3.2 23.4 ± 2.4 23.9 ± 3.0 24.3 ± 2.9
Gender (%)
Male 174 (67.2) 22 (78.6) 125 (69.1) 27 (73.0)
Female 85 (32.8) 6 (21.4) 56 (30.9) 10 (27.0)
Smoking status (%)
No 166 (64.2) 17 (60.7) 116 (64.1) 25 (67.6)
Yes 93 (35.8) 11 (39.3) 65 (35.9) 12 (32.4)
Laterality (%)
Left 147 (56.8) 17 (60.7) 88 (48.6) 16 (43.2)
Right 112 (43.2) 11 (39.3) 93 (51.4) 21 (56.8)
Clinical N stage 
N0 240 (92.7) 6 (21.4) 180 (99.4) 34 (91.9)
N+ 19 (7.3) 22 (78.6) 1 (0.6) 3 (8.1)
Tumour size (mm, mean ± SD) 38.1 ± 24.7 52.9 ± 30.7 36.7 ± 26.5 40.8 ± 22.8
Tumour location (%)
Renal pelvis 94 (36.3) 11 (39.3) 64 (35.4) 16 (43.2)
Ureter 136 (52.5) 13 (46.4) 90 (49.7) 13 (35.1)
Both 29 (11.2) 4 (14.3) 27 (14.9) 8 (21.7)
Previous or concomitant BC (%)
No 207 (79.9) 24 (85.7) 147 (81.2) 30 (81.1)
Yes 52 (20.1) 4 (14.3) 34 (18.8) 7 (18.9)
Bladder cuff resection (%)
No 29 (11.2) 4 (14.3) 21 (11.6) 6 (16.2)
Yes 230 (88.8) 24 (85.7) 160 (88.4) 31 (83.8)
Multifocality (%)
No 164 (63.3) 17 (60.7) 141 (77.9) 27 (73.0)
Yes 95 (36.7) 11 (39.3) 40 (22.1) 10 (27.0)
Pathologic T stage, (%)
Ta, T1, CIS, T2 141 (54.4) 5 (17.9) 137 (75.7) 12 (32.4)
T3-T4 118 (45.6) 23 (82.1) 44 (24.3) 25 (67.6)
Grade (%)
Low 81 (31.3) 3 (10.7) 45 (24.9) 4 (10.8)
High 178 (68.7) 25 (89.3) 136 (75.1) 33 (89.2)
Margin status, (%)
Negative 245 (94.6) 24 (85.7) 177 (97.8) 33 (89.2)
Positive 14 (5.4) 4 (14.3) 4 (2.2) 4 (10.8)
BC: bladder cancer; BMI: body mass index; SD: standard deviation.
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marker predicting the MFS, CCS, and OS (supplementary 
Fig. 1).
Discussion	
In the present study, we showed that N+ patients (Group 
2) had worse prognostic outcomes regarding MFS, CSS, 
and OS than those in the other groups. According to the 
European guidelines on UTUC, LND should be performed 
in association with RNU for better tumour staging and to 
improve prognosis;10 however, LND is not routinely per-
formed during RNU and many patients will experience 
regional LN relapse during followup.24 Therefore, knowl-
edge of LN status is important because it influences patient 
Fig 1. Effect of lymph node (LN) and lymphovasclular invasion (LVI) status on (A) bladder recurrence; and (B) locoregional recurrence/distant metastasis after 
radical nephroureterctomy. Patients were divided into node negative (N0, Group 1); node positive (N+, Group 2); no lymph node dissection (LND) without LVI (NxLVI-, 
Group 3); and no LND with LVI present (NxLVI+, Group 4). 
Table 2. Univariate and multivariate Cox regression analyses to identify predictors of locoregional recurrence/distant 
metastasis in patients with UTUC
Parameters
Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
Age 1.020 (1.002−1.038) 0.025 1.017 (0.997−1.036) 0.096
Gender (male vs. female) 0.951 (0.653−1.385) 0.795 − −
Smoking (no vs. yes) 0.952 (0.618−1.466) 0.823 − −
Tumour size 1.007 (1.001−1.012) 0.018 1.000 (0.994−1.006) 0.997
Tumour location
Renal pelvis 1 − 1 -
Ureter 1.176 (0.793−1.743) 0.42 0.971 (0.637−1.480) 0.892
Both 1.847 (1.123−3.038) 0.016 1.613 (0.942−2.761) 0.081
Bladder cuff resection (no vs. yes) 0.274 (0.195−0.917) 0.019 0.629 (0.370−1.069) 0.087
Multifocality (no vs. yes) 1.180 (0.821−1.695) 0.371 − −
Pathologic T stage (Ta, CIS, T1–2 vs. T3–4) 3.274 (2.051−5.226) <0.001 1.786 (1.065−2.996) 0.028
Grade (low vs. high) 4.992 (2.686−9.278) <0.001 4.251 (2.146−8.421) <0.001
Concomitant CIS (no vs. yes) 0.999 (0.481−2.031) 0.975 − −
Margin status (no vs. yes) 4.979 (3.054−8.116) <0.001 3.741 (2.195−6.375) <0.001
LVI and LN status
Group 1 (N0) 1 − 1 −
Group 2 (N+) 6.834 (4.061−11.500) <0.001 5.896 (3.428−10.141) <0.001
Group 3 (NxLVI-) 1.203 (0.802−1.805) 0.372 1.187 (0.778−1.811) 0.425
Group 4 (NxLVI+) 2.281 (1.283−4.058) 0.005 1.549 (0.861−2.786) 0.144
CI: confidence interval; CIS: carcinoma in situ; HR: hazard ratio; LVI: lymphovascular invasion; LN: lymph node; UTUC: upper tract urothelial carcinoma. 
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counselling and, more importantly, clinical decision-mak-
ing regarding followup scheduling and adjuvant chemo-
therapy.25,26
A recent meta-analysis identified LVI as a strong predictor 
of poor prognosis among patients with UTUC.27 Consistent 
with previous studies, our results showed that Group 4 
(NxLVI+) patients had worse pathological features than 
Groups 1 (N0) and 3 (NxLVI-) patients in terms of T stage 
and grade; however, despite the fact that Group 4 patients 
had worse MFS than those in Groups 1 and 3 in the uni-
variate analysis, Group 4 (NxLVI+) was not an independent 
predictor of MFS compared to the patients in Group 1 (N0) 
based on multivariate Cox regression analysis. Furthermore, 
patients in Group 4 (NxLVI+) showed no additional prog-
nostic advantages regarding OS and CSS compared to those 
in Group 1 (N0). Therefore, whether LVI is a universal prog-
nostic marker for UTUC and a surrogate for LN involvement 
remains unclear. Previous studies supporting our results 
showed that LVI is not an independent predictor of MFS28-
31 and CCS.28,29,32,33 A recent study among Korean UTUC 
patients showed that LVI was not a significant predictor for 
OS.9 In a Taiwanese study by Lee et al, LVI represented a 
significant prognosticator for both CSS and MFS in multivari-
ate analysis only in patients with ureteral tumours, but not 
in those with pyelocaliceal tumours.34 In other words, LVI 
failed to be independently associated with CSS and MFS in 
pyelocaliceal tumours. They concluded that the prognostic 
value of LVI is further highlighted with respect to ureteral 
tumours specifically.
In the present study, subgroup analysis of patients with 
Nx disease showed that LVI status had a negative impact on 
MFS and CSS on univariate analysis; however, we failed to 
find a negative impact of LVI on RFS and CSS on multivariate 
analysis. These results were in accordance with the report 
from Colin et al,35 who assessed the risk factors of metas-
tasis in UTUC patients undergoing RNU without LND. LVI 
status was not significantly associated with worse MFS on 
multivariate analysis.35 In the present study, the independent 
prognostic factors for RFS and CSS among the patients with 
Nx disease were pathologic T stage and positive surgical 
margin. These factors were also identified as independent 
prognostic indicators in the subgroup of patients with pN0/x 
disease in a recent study;36 however, this study showed that 
LVI was a significant prognostic factor on multivariate analy-
sis. In our subgroup analysis including N0 and N1 patients, 
LVI remained a useful predictor for MFS, CSS, and OS, in 
agreement with previous results,36 which suggests that LVI 
is an important factor in patients who undergo LND, but 
not in those who do not undergo LND. Therefore, LND, 
which lacks standardization in UTUC, should be performed 
to improve the prediction of prognosis and the establishment 
of an adjuvant therapy schedule. A recent study showed 
that LVI was a significant predictor for CSS in the Nx group 
and might be used as a surrogate marker in patients who 
do not undergo LDN at the time of surgery;20 however, this 
study had a limited population size (n=131), and other well-
known independent predictors, such as pathologic T stage, 
were not included as significant variables in multivariate 
analysis. Therefore, the establishment of standardized guide-
lines for the management of UTUC patients requires further 
investigation.
Our study had several limitations associated with its ret-
rospective nature. Although we could control for numer-
ous potential confounders, we were unable to control for 
Fig 2. Effect of lymph node (LN) and lymphovasclular invasion (LVI) status on (A) cancer-specific survival; and (B) overall survival after radical nephroureterctomy. 
Patients were divided into node negative (N0, Group 1); node positive (N+, Group 2); no lymph node dissection (LND) without LVI (NxLVI-, Group 3); and no LND with 
LVI present (NxLVI+, Group 4). 
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surgeon and pathologist experience, treatment decisions 
(such as patient and surgeon preferences), or the anatomi-
cal template of the preferred LND. Relatively short periods 
of followup warranted consideration. Moreover, we did not 
report the information of the LN yield from surgeries at the 
centre. The other limitation of our study is the small number 
of cases in Groups 2 and 4. 
Conclusions
Although LVI was a predictor of poor outcome in patients 
with UTUC, it could not replace LN positivity as a prog-
nostic marker. In particular, LVI did not provide important 
prognostic information in patients with Nx. Therefore, LVI 
may not be used as a substitute for nodal status in patients 
who do not undergo LND at the time of surgery. 
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Supplementary Table 1. Subgroup analyses of the patients with Nx: Univariate and multivariate Cox regression analyses to 
identify predictors of locoregional recurrence/distant metastasis
Parameters
Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
Age 1.013 (0.987−1.039) 0.34 − −
Gender (male vs. female) 0.660 (0.356−1.223) 0.186 − −
Smoking (no vs. yes) 1.045 (0.588−1.857) 0.88 − −
Tumour size 1.000 (0.991−1.009) 0.959 − −
Tumour location
Renal pelvis 1 − − −
Ureter 1.489 (0.805−2.755) 0.205 − −
Both 1.966 (0.959−4.030) 0.065 − −
Bladder cuff resection (no vs. yes) 0.598 (0.302−1.181) 0.139 − −
Multifocality (no vs. yes) 1.224 (0.694−2.156) 0.485 − −
Pathologic T stage (Ta, CIS, T1–2 vs. T3–4) 2.898 (1.729−4.859) <0.001 2.355 (1.340−4.256) 0.005
Grade (low vs. high) 2.802 (1.267−6.201) 0.011 1.771 (0.760−4.123) 0.185
Concomitant CIS (no vs. yes) 1.497 (0.678−3.306) 0.318 − −
Margin status (no vs. yes) 5.665 (2.561−12.530) <0.001 4.556 (1.983−10.465) <0.001
LVI (no vs. yes) 1.886 (1.047−3.395) 0.035 1.063 (0.547−2.066) 0.185
CI: confidence interval; CIS: carcinoma in situ; HR: hazard ratio; LVI: lymphovascular invasion; UTUC: upper tract urothelial carcinoma. 
Supplementary Table 2. Subgroup analyses of the patients with Nx: Univariate and multivariate Cox regression analyses to 
identify predictors of cancer specific survival
Parameters
Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
Age 1.034 (0.991−1.078) 0.126 − −
Gender (male vs. female) 1.095 (0.472−2.538) 0.833 − −
Smoking (no vs. yes) 0.621 (0.227−1.697) 0.353 − −
Tumour size 1.003 (0.991−1.015) 0.639 − −
Tumour location
Renal pelvis 1 − − −
Ureter 0.813 (0.305−2.169) 0.679 − −
Both 2.280 (0.878−5.922) 0.091 − −
Bladder cuff resection (no vs. yes) 0.408 (0.163−1.024) 0.056 − −
Multifocality (no vs. yes) 1.507 (0.663−3.423) 0.328 − −
Pathologic T stage (Ta, CIS, T1–2 vs. T3–4) 4.903 (2.161−11.126) <0.001 4.432 (1.823−10.771) 0.001
Grade (low vs. high) 4.244 (0.998−18.050) 0.05 − −
Concomitant CIS (no vs. yes) 0.960 (0.226−4.077) 0.956 − −
Margin status (no vs. yes) 5.654 (1.928−16.582) <0.002 4.238 (1.382−13.002) 0.012
LVI (no vs. yes) 2.406 (1.037−5.581) 0.041 1.073(0.419−2.749) 0.185
CI: confidence interval; CIS: carcinoma in situ; HR: hazard ratio; LVI: lymphovascular invasion; UTUC: upper tract urothelial carcinoma. 
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Suppl. Fig 1. Prognostic values of lymphovascular invasion (LVI) in patients with lymph node dissection (LND) (N0 and N1).
